Multiple sclerosis and related disorders · 2026
Diagnosis and antibody status awareness in neuromyelitis optica spectrum disorder and MOG-associated disease: A cross-sectional study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Apóstolos-Pereira Samira Luisa, Terrim Sara, Santana de Araujo Roger, Simon Nogueira Ana Beatriz, Macedo de Souza Tieppo Eduardo, Aguiar Santos Faria Graziella, Baleeiro Rodrigues Silva Paula, Vieira Marques Filho Flávio, Santillan Thiago, Rosalem Rafael, Holanda Arthur, Silva Guilherme Diogo, Adoni Tarso, Callegaro Dagoberto
Аннотация
INTRODUCTION: Neuromyelitis optica spectrum disorder (NMOSD) and MOG-associated disease (MOGAD) present high risk of disability. Early testing for anti-aquaporin-4 (AQP4) and anti-myelin oligodendrocyte glycoprotein (MOG) antibodies is crucial for timely diagnosis and better outcomes. However, patient awareness of these antibodies and their understanding about their disease remains poorly characterized.
OBJECTIVES/AIMS: To assess the frequency of antibody serostatus awareness and diagnosis recognition among patients with NMOSD and MOGAD in a tertiary outpatient clinic.
METHODS: In this cross-sectional study (March 2023 to October 2024), we surveyed patients with AQP4-positive NMOSD, MOGAD and double-seronegative optic neuritis or longitudinally extensive transverse myelitis with a structured questionnaire evaluating their understanding of diagnosis and antibody status. We extracted demographic and clinical data from medical records and analyzed factors related to disease awareness.
RESULTS: We included 98 patients (81 % female): 57 with AQP4-positive NMOSD, 16 with MOGAD, and 25 double-seronegative. Median age at diagnosis was 36 years (IQR 30-47.5). Self-reported ethnicity was Black or mixed in 63 %, White in 32 %, and Asian in 5 %. Median years of education was 12 (IQR 8-12). Awareness of antibody status was reported by 34/57 (60 %) AQP4-positive and 11/16 (69 %) MOGAD patients. In univariate analyses, antibody awareness was associated with years of education (p = 0.0006), age at diagnosis (p = 0.0001), and age at onset (p = 0.001). In multivariable analysis, years of education remained independently associated, with each additional year increasing the odds of awareness by 32 % (OR 1.32, 95 % CI 1.11-1.63).
CONCLUSION: Almost half of the patients lacked information about their antibody status. Better communication and patient education could strengthen understanding, promote engagement in care, and reduce delays in diagnosis and treatment. Questions about how social determinants of health may impact in aptitude to hunt for proper and early diagnosis and treatment need to be more evaluated in the NMOSD/MOGAD scenario.
OBJECTIVES/AIMS: To assess the frequency of antibody serostatus awareness and diagnosis recognition among patients with NMOSD and MOGAD in a tertiary outpatient clinic.
METHODS: In this cross-sectional study (March 2023 to October 2024), we surveyed patients with AQP4-positive NMOSD, MOGAD and double-seronegative optic neuritis or longitudinally extensive transverse myelitis with a structured questionnaire evaluating their understanding of diagnosis and antibody status. We extracted demographic and clinical data from medical records and analyzed factors related to disease awareness.
RESULTS: We included 98 patients (81 % female): 57 with AQP4-positive NMOSD, 16 with MOGAD, and 25 double-seronegative. Median age at diagnosis was 36 years (IQR 30-47.5). Self-reported ethnicity was Black or mixed in 63 %, White in 32 %, and Asian in 5 %. Median years of education was 12 (IQR 8-12). Awareness of antibody status was reported by 34/57 (60 %) AQP4-positive and 11/16 (69 %) MOGAD patients. In univariate analyses, antibody awareness was associated with years of education (p = 0.0006), age at diagnosis (p = 0.0001), and age at onset (p = 0.001). In multivariable analysis, years of education remained independently associated, with each additional year increasing the odds of awareness by 32 % (OR 1.32, 95 % CI 1.11-1.63).
CONCLUSION: Almost half of the patients lacked information about their antibody status. Better communication and patient education could strengthen understanding, promote engagement in care, and reduce delays in diagnosis and treatment. Questions about how social determinants of health may impact in aptitude to hunt for proper and early diagnosis and treatment need to be more evaluated in the NMOSD/MOGAD scenario.